Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc
Advaxis in Drug Licensing Discussions for Its Flagship Vaccine Construct, ADXS11-001
May 8th, 2009
Advaxis, Inc. (OTCBB: ADXS) is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets. Due to the potential materiality of the aforementioned event, Advaxis ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed. ADXS11-001 is a therapeutic vaccine, like Dendreon’s Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer...
Source: Health Business Week (2009-05-08)
|
